background
โรงพยาบาลจุฬาลงกรณ์
นัดหมายพบแพทย์
รศ.ดร.นพ.วิโรจน์ ศรีอุฬารพงศ์

Education

1984-1990 Doctor of Medicine (honored), Chulalongkorn University, Thailand
1990-1994 Diploma of Internal Medicine, Thai Medical Council, Thailand
1994-1996 Fellow in Medical Oncology, Chulalongkorn University, Thailand
1997-2001 Ph.D. in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, US
2001-2003 Visiting Fellow, Oral and Pharyngeal Cancer Branch, National Institute of Dental and
  Craniofacial Research, National Institutes of Health, Bethesda, MD, US


Professional Experiences

1990-1994 House Physician, Department of Medicine, Cholburi Hospital, Ministry of Public Health, Thailand
1996-2005 Instructor in Internal Medicine and Medical Oncology, Chulalongkorn University, Bangkok, Thailand
2004-2012 Chief, Medical Oncology Unit, Department of Medicine, Chulalongkorn University, Bangkok, Thailand
2004-2008 Academic Affairs, Thai Society of Clinical Oncology
2014-present President, Thai Society of Clinical Oncology
2008-present Committee Member, Academic Affairs, the Royal College of Thai Physicians
2005-2012 Assistant Professor in Internal Medicine and Medical Oncology, Chulalongkorn University, 
  Bangkok, Thailand
2012-present Associate Professor in Internal Medicine and Medical Oncology, Chulalongkorn University,
  Bangkok, Thailand
2016-present Director of Chulalongkorn Comprehensive Cancer Center


Award and Honor

1997-2001 Royal Thai Government Scholarship
2000 AACR-AFLAC, Inc. Scholars in Cancer Research in 91st AACR Annual Meeting
2005-2007 Recipient of the MUA-TRF New Researcher Grant, from the Ministry of University Affairs and
   the Thailand Research Funds.
2008-2010 Recipient of the MUA-TRF Mid-level Researcher Grant, from the Ministry of University Affairs and
  the Thailand Research Funds.
2010-2012 Ethnic Research Initiatives Research Grant, Glaxo International Oncology.

 

Publications

Sriuranpong V, Voravud N. Antineoplastic-associated colitis in Chulalongkorn University Hospital. J Med Assoc Thai1995 Aug;78(8):424-30.


Mutirangura A, Supiyaphun P, Trirekapan S, Sriuranpong V, Sakuntabhai A, Yenrudi S, Voravud N. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res1996 Aug 1;56(15):3530-3.


Mutirangura A, Tanunyutthawongese C, Kerekhanjanarong V, Sriuranpong V, Pornthanakasem W, Yenrudi S, Supiyaphun P, Voravud N. Loss of heterozygosity for chromosome 11 in Epstein-Barr-virus associated nasopharyngeal carcinoma. J Med Assoc Thai1996 Dec;79 Suppl 1:S65-70.


Tanunyutthawongese C, Sriuranpong V, Kerekhanjanarong V, Changchup B, Yenrudi S, Supiyaphun P, Voravud N, Mutirangura A. Microsatellite instability in Epstein-Barr virus associated with nasopharyngeal carcinoma. J Med Assoc Thai1996 Dec;79 Suppl 1:S71-7.


Mutirangura A, Tanunyutthawongese C, Pornthanakasem W, Kerekhanjanarong V, Sriuranpong V, Yenrudi S, Supiyaphun P, Voravud N. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer1997;76(6):770-6.


Charuruks N, Voravud N, Sriuranpong V. MPXI and early neutrophilia: new potential therapeutic biomarkers for recombinant human granulocyte colony-stimulating factor. J Clin Lab Anal1998;12(1):41-6.


Mutirangura A, Pornthanakasem W, Sriuranpong V, Supiyaphun P, Voravud N. Loss of heterozygosity on chromosome 14 in nasopharyngeal carcinoma. Int J Cancer1998 Oct 5;78(2):153-6.


Mutirangura A, Pornthanakasem W, Theamboonlers A, Sriuranpong V, Lertsanguansinchi P, Yenrudi S, Voravud N, Supiyaphun P, Poovorawan Y. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. Clin Cancer Res1998 Mar;4(3):665-9.


Mutirangura A, Sriuranpong V, Termrunggraunglert W, Tresukosol D, Lertsaguansinchai P, Voravud N, Niruthisard S. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. Br J Cancer1998 Oct;78(7):933-9.


Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol1998 Aug;21(4):386-91.


Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med1998 Jul;4(7):747-8.


Mutirangura A, Charuruks N, Shuangshoti S, Sakdikul S, Chatsantikul R, Pornthanakasem W, Sriuranpong V, Supiyaphun P, Voravud N. Identification of distinct regions of allelic loss on chromosome 13q in nasopharyngeal cancer from paraffin embedded tissues. Int J Cancer1999 Oct 8;83(2):210-4.


Voravud N, Sriuranpong V, Lertsaguansinchai P. Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma. J Med Assoc Thai2000 Feb;83(2):123-8.


Nakakura EK, Watkins DN, Schuebel KE, Sriuranpong V, Borges MW, Nelkin BD, Ball DW. Mammalian Scratch: a neural-specific Snail family transcriptional repressor. Proc Natl Acad Sci U S A2001 Mar 27;98(7):4010-5.


Nakakura EK, Watkins DN, Sriuranpong V, Borges MW, Nelkin BD, Ball DW. Mammalian Scratch participates in neuronal differentiation in P19 embryonal carcinoma cells. Brain Res Mol Brain Res2001 Nov 1;95(1-2):162-6.


Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res2001 Apr 1;61(7):3200-5.


Sriuranpong V, Borges MW, Strock CL, Nakakura EK, Watkins DN, Blaumueller CM, Nelkin BD, Ball DW. Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol Cell Biol2002 May;22(9):3129-39.


Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM, Leach SD. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell2003 Jun;3(6):565-76.


Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res2003 Jun 1;63(11):2948-56.


Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res2004 Jun 15;10(12 Pt 1):4029-37.


Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D, Voravud N, Sriuranpong V, Mutirangura A. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene2004 Nov 18;23(54):8841-6.


Sriuranpong V, Mutirangura A, Gillespie JW, Patel V, Amornphimoltham P, Molinolo AA, Kerekhanjanarong V, Supanakorn S, Supiyaphun P, Rangdaeng S, Voravud N, Gutkind JS. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin Cancer Res2004 Aug 1;10(15):4944-58.


Chantranuwat C, Sriuranpong V, Huapai N, Chalermchai T, Leungtaweeboon K, Voravud N, Mutirangura A. Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation. J Med Assoc Thai2005 Sep;88 Suppl 4:S322-9.


List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev2005 Aug 15;19(16):1934-50.


Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab2005 Jul;90(7):4350-6.


Voravud N, Sriuranpong V. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. J Med Assoc Thai2005 Dec;88(12):1790-6.


Voravud N, Sriuranpong V. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. J Med Assoc Thai2005 May;88(5):607-12.